Investment Thesis
Wellgistics Health exhibits severe financial distress with negative stockholders' equity of -$15.1M indicating technical insolvency. The company is experiencing critical liquidity crisis (0.09x current ratio, $51.7K cash) while burning $3.4M quarterly in operations, making near-term solvency highly questionable despite 28.7% revenue growth.
Strengths
- Revenue growth of 28.7% YoY demonstrates market demand for products
- Positive gross profit ($170.2K) indicates viable unit economics at product level
- Low revenue base ($1.6M) leaves room for improvement if operational losses are arrested
Risks
- Negative stockholders' equity of -$15.1M signals technical insolvency; liabilities exceed assets by $15.1M
- Critical liquidity failure: current ratio 0.09x, quick ratio 0.03x, only $51.7K cash available
- Operating cash burn of -$3.4M quarterly with accelerating net losses (-1377.1% YoY) unsustainable
- Debt burden of $27.8M cannot be serviced with current cash generation; maturity risk imminent
- Operating margin of -385.7% indicates structural unprofitability requiring existential restructuring
Key Metrics to Watch
- Quarterly cash runway and monthly operating cash burn rate trajectory
- Debt refinancing progress or restructuring negotiations with lenders
- Revenue-to-operating-expense ratio improvement and path to operating cash flow breakeven
- Stockholders' equity recovery and changes in liquidity ratios (current/quick ratio floor)
- Any capital infusions, dilutive financing, or covenant violations
Financial Metrics
Revenue
1.6M
Net Income
-7.7M
EPS (Diluted)
$-0.07
Free Cash Flow
-3.4M
Total Assets
30.1M
Cash
51.7K
Profitability Ratios
Gross Margin
10.9%
Operating Margin
-385.7%
Net Margin
-496.5%
ROE
N/A
ROA
-25.7%
FCF Margin
-218.9%
Balance Sheet & Liquidity
Current Ratio
0.09x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
150.0%
Interest Coverage
N/A
Long-term Debt
27.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-21T07:14:59.991200 |
Data as of: 2026-03-31 |
Powered by Claude AI